PROCEPT BioRobotics Corporation Common Stock (PRCT)
PROCEPT BioRobotics Corporation (PRCT) is a medical device company focused on developing innovative solutions for the treatment of benign prostatic hyperplasia (BPH). The company is known for its Water Vapor Therapy platform, which uses controlled water vapor to ablate excess prostate tissue, offering a minimally invasive option for patients. Founded to advance urological care, PROCEPT aims to improve patient outcomes with technology that simplifies BPH treatment procedures.
Company News
Procept BioRobotics reported strong Q2 2025 financial results with 48.3% revenue growth, reaching $79.2 million, driven by increased U.S. and international sales of robotic surgical systems for BPH treatment.
PROCEPT BioRobotics announced leadership transition with Dr. Reza Zadno retiring and Larry L. Wood becoming the new president and CEO effective September 2, 2025. The company also pre-announced Q2 2025 revenue of $79.2 million, representing 48% annual growth.
Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 7.27% and 6.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?